You are here: Industry Insights > Exothera

News List

ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries PharmaSources.com
April 12, 2022
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0. PharmaSources.com
April 07, 2022
Rokote Laboratories Finland Ltd., a vaccine development company focusing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.
GMP certification for Exothera further extends its viral vector manufacturing capacity PharmaSources.com
March 24, 2022
Exothera S.A., a CDMO specialized in the development and manufacture of viral vectors for vaccines and gene therapies, received Good Manufacturing Practices (GMP) certification from the Federal Agency for Medicines and Health Products...
Thibault Jonckheere Named CEO of Exothera contractpharma
June 02, 2021
The viral vector CDMO spinoff of Univercells is making an intranasal vaccine candidate for Covid-19 treatment.
CyanVac and Exothera Enter COVID-19 Vaccine Partnership contractpharma
March 26, 2021
CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.
CyanVac Selects Exothera for the Development and GMP Manufacturing of its COVID-19 Intranasal Vaccine Candidate for Phase III Clinical Trial is Europe and the US PharmaSources.com
March 25, 2021
CyanVac LLC, a vaccine company, announced that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and manufacturing of their COVID-19 intranasal vaccine based on a ...
Exothera expands range of state-of-the-art technologies by acquiring the NevoLine™ Upstream platform for Belgium site PharmaSources.com
February 01, 2021
JUMET, BELGIUM – January 28, 2021 – Exothera S.A., announces today that it has acquired the NevoLine™ Upstream manufacturing platform, the latest equipment of Univercells Technologies.
Univercells Launches Cell & Gene Therapy CDMO Exothera contractpharma
March 23, 2020
Will partner with innovators to unlock their manufacturing potential by capitalizing on best-in-class manufacturing technologies and bioprocessing expertise.